Also known as: Prostate Bioregulator, Prostamax Khavinson Peptide
Half-life: Short (minutes); biological effect persists via gene-expression modulation
Last reviewed: · Published:
Prostamax is a short peptide bioregulator from the Khavinson family, designed for prostate health applications. It is proposed to target prostate epithelial gene expression to support normal prostate function, reduce inflammation in chronic prostatitis, and potentially modulate benign prostatic hyperplasia (BPH) progression. The compound is used in Russian clinical practice for chronic prostatitis, BPH, and as a general prostate-support measure in aging men.
Russian clinical-observational studies have reported improvements in IPSS (International Prostate Symptom Score), urinary flow measures, and inflammatory markers in patients with chronic prostatitis and BPH. The clinical evidence base is similar in character to that of other Khavinson bioregulators — predominantly Russian, predominantly observational, with limited Western validation.
Prostamax is sold by research-chemical vendors outside Russia. It should not be used as a substitute for proven BPH therapies (alpha-blockers, 5-alpha-reductase inhibitors) or as a substitute for proper urological evaluation in men with prostate symptoms, where ruling out malignancy is essential.
Prostamax was developed in the 2000s as part of the Khavinson bioregulator program for urological applications. The compound entered Russian clinical observational use in urology contexts through the 2000s and 2010s.
Russian clinical use has reported good tolerability in urological patient populations. Western safety validation is essentially absent. Men with prostate symptoms should undergo proper urological evaluation (DRE, PSA, possibly imaging) before relying on any single agent for management — peptide bioregulators do not address the diagnostic question of whether symptoms represent BPH, chronic prostatitis, or malignancy.
Dose Range
1-5 mg
Frequency
Once daily (SubQ) or sublingual
Duration
10-20 day cycles, repeated 2-3 times per year
Dosing information is for educational purposes only. Consult a healthcare professional before using any peptide.
Typical Vial Size
20 mg
Water Type
Bacteriostatic water (BAC water)
Mixing Volume
2 mL
Half-Life
Short (minutes); biological effect persists via gene-expression modulation
Molecular Weight
~400-600 Da
Store reconstituted vial refrigerated at 2-8°C. Use within 21-30 days. Sublingual or subcutaneous administration is typical.
FDA Status
Not FDA approved.
Legal Status
Unregulated research chemical outside Russia.
USA
Not approvedResearch-only
EU
Not approvedNot authorized as medicinal product
UK
Not approvedClassified as research chemical
Russia
Used in clinical practiceUsed as bioregulator in Russian urology
Australia
Not approvedTGA has not evaluated
Canada
Not approvedNot authorized for human use
Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS
Bulletin of Experimental Biology and Medicine (2015)
Foundational Khavinson-group review covering the full short-peptide bioregulator family including Prostamax.
View Study →Khavinson VK, Anisimov VN, Linkova NS, Bakhmet AA
Bulletin of Experimental Biology and Medicine (2020)
Modern Khavinson-group mechanistic review applicable to all tissue-targeting bioregulators including Prostamax.
View Study →Khavinson VK, Morozov VG, Anisimov VN
Advances in Gerontology (2016)
Russian-group review of peptide bioregulators in urological applications, providing observational support for Prostamax and related compounds in chronic prostatitis and BPH contexts.
View Study →Khavinson short peptide bioregulator targeting testicular tissue.
Khavinson short peptide bioregulator targeting urinary bladder epithelium.
Khavinson short peptide bioregulator targeting thymus / immune cells.
Track Prostamax and more with PinnyPeptide.
Sign Up to Track ProstamaxFree forever · defaults pre-filled from this article